Aortic Valve Replacement Devices Market Size, Share and Growth Outlook, 2026

Aortic Valve Replacement Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Aortic Valve Replacement Devices Market size is forecast to increase from $8.92 Billion in 2026 to $19.54 Billion in 2034 at a CAGR of 10.3% between 2026 and 2034.

The Aortic Valve Replacement Devices market report provides detailed analysis and outlook of Aortic Valve Replacement Devices segments including By Product Type (Transcatheter Aortic Valve Replacement, Biological / Tissue Surgical Valves, Mechanical Surgical Valves, Sutureless / Rapid-Deployment Valves), By TAVR Frame Mechanism (Balloon-Expandable Systems, Self-Expandable Systems, Mechanically Expandable Systems), By Target Clinical Indication (Aortic Stenosis, Aortic Regurgitation / Insufficiency), By End-User (Hospitals and Tertiary Heart Centers, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Aortic Valve Replacement Devices Industry Overview

Advancements in Transcatheter and Surgical Aortic Valve Replacement Technologies

The aortic valve replacement devices industry is experiencing continuous innovation driven by the increasing adoption of minimally invasive cardiovascular procedures and the growing focus on improving outcomes for patients with complex valvular heart diseases. Technological advancements in transcatheter aortic valve replacement (TAVR) systems, enhanced valve designs, and improved procedural techniques are expanding treatment options for patients who may not be suitable candidates for conventional surgery. Healthcare providers are increasingly emphasizing early diagnosis and intervention for aortic valve disorders, supporting greater utilization of both transcatheter and surgical valve replacement procedures. At the same time, manufacturers are investing in clinical research and next-generation device development to address long-term performance, durability, and patient-specific treatment needs.

Regulatory Progress Expands Treatment Options for Aortic Regurgitation

A significant milestone in the industry was the FDA premarket approval of the Trilogy™ Transcatheter Heart Valve System developed by JenaValve Technology, Inc. The device became the first and only transcatheter heart valve in the United States specifically indicated for the treatment of symptomatic, severe aortic regurgitation (AR) in patients who are considered high risk for surgical valve replacement. The approval was supported by data from the ALIGN-AR Pivotal Trial, highlighting the growing clinical acceptance of transcatheter therapies beyond traditional aortic stenosis treatment. This development addresses a critical unmet need in structural heart disease management and reflects the industry's ongoing efforts to expand transcatheter valve applications to broader patient populations. As physicians seek less invasive treatment alternatives, dedicated solutions for aortic regurgitation are expected to play an increasingly important role in cardiovascular care.

Growing Adoption of TAVR and Ongoing Durability Discussions

Commercial performance and clinical evidence continue to shape the competitive landscape of the aortic valve replacement devices market. Edwards Lifesciences reported strong growth in its TAVR business, with sales reaching $1.2 billion and increasing by 14.4% year over year. The company attributed this performance to evolving clinical practice patterns that emphasize proactive disease management and earlier referral of patients with severe aortic stenosis, prompting an increase in its annual sales growth guidance to between 9% and 11%. Meanwhile, long-term clinical findings from the Evolut Low Risk trial published in the Journal of the American College of Cardiology highlighted important considerations regarding valve durability. The seven-year data demonstrated a statistically significant 3.8% difference in reintervention rates favoring surgical aortic valve replacement (SAVR) over transcatheter aortic valve implantation (TAVI), stimulating ongoing discussions among clinicians regarding long-term treatment selection and durability expectations for low-risk patient populations.

Aortic Valve Replacement Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Aortic Valve Replacement Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Artivion, Inc., Venus Medtech, JenaValve Technology, Inc., CryoLife, Inc.. The Aortic Valve Replacement Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Aortic Valve Replacement Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Aortic Valve Replacement Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Aortic Valve Replacement Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Aortic Valve Replacement Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Aortic Valve Replacement Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Aortic Valve Replacement Devices industry include- Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Artivion, Inc., Venus Medtech, JenaValve Technology, Inc., CryoLife, Inc.. The Aortic Valve Replacement Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Aortic Valve Replacement Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Aortic Valve Replacement Devices market remains one of the strongest-performing segments in the country.
The US Aortic Valve Replacement Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Aortic Valve Replacement Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Aortic Valve Replacement Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Aortic Valve Replacement Devices markets

Canada's strong Aortic Valve Replacement Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Aortic Valve Replacement Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Aortic Valve Replacement Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Aortic Valve Replacement Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Aortic Valve Replacement Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Aortic Valve Replacement Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Aortic Valve Replacement Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Aortic Valve Replacement Devices sales through 2034

France Aortic Valve Replacement Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Aortic Valve Replacement Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Aortic Valve Replacement Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Aortic Valve Replacement Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Aortic Valve Replacement Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Aortic Valve Replacement Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Aortic Valve Replacement Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Aortic Valve Replacement Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Aortic Valve Replacement Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Aortic Valve Replacement Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Aortic Valve Replacement Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Aortic Valve Replacement Devices Market Segmentation

By Product Type
Transcatheter Aortic Valve Replacement
Biological / Tissue Surgical Valves
Mechanical Surgical Valves
Sutureless / Rapid-Deployment Valves
By TAVR Frame Mechanism
Balloon-Expandable Systems
Self-Expandable Systems
Mechanically Expandable Systems
By Target Clinical Indication
Aortic Stenosis
Aortic Regurgitation / Insufficiency
By End-User
Hospitals and Tertiary Heart Centers
Cardiac Catheterization Laboratories
Ambulatory Surgical Centers

Top Companies in Aortic Valve Replacement Devices Industry

Edwards Lifesciences Corporation
Medtronic plc
Abbott Laboratories
Boston Scientific Corporation
LivaNova PLC
Meril Life Sciences Pvt. Ltd.
Artivion, Inc.
Venus Medtech
JenaValve Technology, Inc.
CryoLife, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025